These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

324 related items for PubMed ID: 12579271

  • 1. Identification of markers of possible prognostic value in 57 giant cell tumors of bone.
    Gamberi G, Serra M, Ragazzini P, Magagnoli G, Pazzaglia L, Ponticelli F, Ferrari C, Zanasi M, Bertoni F, Picci P, Benassi MS.
    Oncol Rep; 2003; 10(2):351-6. PubMed ID: 12579271
    [Abstract] [Full Text] [Related]

  • 2. Proteases and interleukin-6 gene analysis in 92 giant cell tumors of bone.
    Gamberi G, Benassi MS, Ragazzini P, Pazzaglia L, Ponticelli F, Ferrari C, Balladelli A, Mercuri M, Gigli M, Bertoni F, Picci P.
    Ann Oncol; 2004 Mar; 15(3):498-503. PubMed ID: 14998856
    [Abstract] [Full Text] [Related]

  • 3. Detection of mRNAs for urokinase-type plasminogen activator, its receptor, and type 1 inhibitor in giant cell tumors of bone with in situ hybridization.
    Zheng MH, Fan Y, Panicker A, Smith A, Robertson T, Wysocki S, Robbins P, Papadimitriou JM, Wood DJ.
    Am J Pathol; 1995 Dec; 147(6):1559-66. PubMed ID: 7495280
    [Abstract] [Full Text] [Related]

  • 4. [Expression and significance of urokinase-type plasminogen activator, its receptor, and type 2 inhibitor in giant cell tumor of bone].
    Li H, Dong S, Zeng Y.
    Zhonghua Zhong Liu Za Zhi; 2001 Sep; 23(5):386-8. PubMed ID: 11810768
    [Abstract] [Full Text] [Related]

  • 5. Urokinase system expression in gastric carcinoma: prognostic impact in an independent patient series and first evidence of predictive value in preoperative biopsy and intestinal metaplasia specimens.
    Beyer BC, Heiss MM, Simon EH, Gruetzner KU, Babic R, Jauch KW, Schildberg FW, Allgayer H.
    Cancer; 2006 Mar 01; 106(5):1026-35. PubMed ID: 16435385
    [Abstract] [Full Text] [Related]

  • 6. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma.
    Hofmann R, Lehmer A, Buresch M, Hartung R, Ulm K.
    Cancer; 1996 Aug 01; 78(3):487-92. PubMed ID: 8697395
    [Abstract] [Full Text] [Related]

  • 7. Prognostic relevance of urokinase type plasminogen activator, its receptor and inhibitors in chondrosarcoma.
    Morii T, Yabe H, Morioka H, Yamada R, Nakagawa T, Toyama Y.
    Anticancer Res; 2000 Aug 01; 20(5A):3031-6. PubMed ID: 11062719
    [Abstract] [Full Text] [Related]

  • 8. Components of the plasminogen activation system in uveal melanoma--a clinico-pathological study.
    De Vries TJ, Mooy CM, Van Balken MR, Luyten GP, Quax PH, Verspaget HW, Weidle UH, Ruiter DJ, Van Muijen GN.
    J Pathol; 1995 Jan 01; 175(1):59-67. PubMed ID: 7891228
    [Abstract] [Full Text] [Related]

  • 9. The urokinase-system in tumor tissue stroma of the breast and breast cancer cell invasion.
    Hildenbrand R, Schaaf A.
    Int J Oncol; 2009 Jan 01; 34(1):15-23. PubMed ID: 19082473
    [Abstract] [Full Text] [Related]

  • 10. Expression of plasminogen activator inhibitors 1 and 2 in lung cancer and their role in tumor progression.
    Robert C, Bolon I, Gazzeri S, Veyrenc S, Brambilla C, Brambilla E.
    Clin Cancer Res; 1999 Aug 01; 5(8):2094-102. PubMed ID: 10473092
    [Abstract] [Full Text] [Related]

  • 11. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone.
    Si AI, Huang L, Xu J, Kumta SM, Wood D, Zheng MH.
    J Cell Biochem; 2003 Aug 15; 89(6):1154-63. PubMed ID: 12898514
    [Abstract] [Full Text] [Related]

  • 12. Expression of matrix metalloproteinases-1, -2, and -9; tissue inhibitors of matrix metalloproteinases-1 and -2; cathepsin B; urokinase plasminogen activator; and plasminogen activator inhibitor, type I in skull base chordoma.
    Naka T, Kuester D, Boltze C, Schulz TO, Samii A, Herold C, Ostertag H, Roessner A.
    Hum Pathol; 2008 Feb 15; 39(2):217-23. PubMed ID: 17949787
    [Abstract] [Full Text] [Related]

  • 13. Expression of plasminogen activators and plasminogen activator inhibitor 1 in dedifferentiated chondrosarcoma.
    Häckel C, Czerniak B, Ayala AG, Radig K, Roessner A.
    Cancer; 1997 Jan 01; 79(1):53-8. PubMed ID: 8988726
    [Abstract] [Full Text] [Related]

  • 14. The prognostic value of polymorphonuclear leukocyte elastase in patients with primary breast cancer.
    Foekens JA, Ries C, Look MP, Gippner-Steppert C, Klijn JG, Jochum M.
    Cancer Res; 2003 Jan 15; 63(2):337-41. PubMed ID: 12543785
    [Abstract] [Full Text] [Related]

  • 15. Spitz naevi may express components of the plasminogen activation system.
    Ferrier CM, Van Geloof WL, Straatman H, Van De Molengraft FJ, Van Muijen GN, Ruiter DJ.
    J Pathol; 2002 Sep 15; 198(1):92-9. PubMed ID: 12210068
    [Abstract] [Full Text] [Related]

  • 16. Expression of urokinase-type plasminogen activator (u-PA), u-PA receptor, and tissue-type PA messenger RNAs in human hepatocellular carcinoma.
    De Petro G, Tavian D, Copeta A, Portolani N, Giulini SM, Barlati S.
    Cancer Res; 1998 May 15; 58(10):2234-9. PubMed ID: 9605771
    [Abstract] [Full Text] [Related]

  • 17. Urokinase-type plasminogen activator system in breast cancer: association with tamoxifen therapy in recurrent disease.
    Meijer-van Gelder ME, Look MP, Peters HA, Schmitt M, Brünner N, Harbeck N, Klijn JG, Foekens JA.
    Cancer Res; 2004 Jul 01; 64(13):4563-8. PubMed ID: 15231667
    [Abstract] [Full Text] [Related]

  • 18. The urokinase plasminogen activator system: a rich source of tumour markers for the individualised management of patients with cancer.
    Duffy MJ, Duggan C.
    Clin Biochem; 2004 Jul 01; 37(7):541-8. PubMed ID: 15234235
    [Abstract] [Full Text] [Related]

  • 19. Urokinase-type plasminogen activator system and breast cancer (Review).
    Han B, Nakamura M, Mori I, Nakamura Y, Kakudo K.
    Oncol Rep; 2005 Jul 01; 14(1):105-12. PubMed ID: 15944776
    [Abstract] [Full Text] [Related]

  • 20. Differential gene expression in classic giant cell tumours of bone: Tenascin C as biological risk factor for local relapses and metastases.
    Pazzaglia L, Conti A, Chiechi A, Novello C, Magagnoli G, Astolfi A, Pession A, Krenacs T, Alberghini M, Picci P, Benassi MS.
    Histopathology; 2010 Jul 01; 57(1):59-72. PubMed ID: 20653781
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.